After dealing with a deployment problem with glucose monitors earlier this year, interim CEO Jake Leach said improving ...

Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

Dexcom faces new FDA reports linking its G7 glucose monitor to patient deaths as lawsuits and regulatory scrutiny intensify.

Medical device maker Dexcom topped Wall Street estimates for third-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring systems.

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...

DexCom, Inc. DXCM is scheduled to report third-quarter 2025 resultson Oct. 30, after the closing bell. In the last reported ...

DexCom, Inc. (NASDAQ:DXCM) is one of the Best Long Term Growth Stocks to Buy Now. On September 19, William Blair analyst Brandon Vazquez maintained their bullish stance on the company’s stock, giving ...

Dexcom (DXCM) shares slipped in midday trade on Tuesday after short seller Hunterbrook reported three additional deaths linked to the company’s G7 continuous glucose monitor. DXCM’s stock fell nearly ...

Amid some scrutiny over its latest-generation G7 CGM, Dexcom officials addressed claims on the company's latest earnings call ...

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include ...

Price rises in the UK are to be the highest among the G7 club of industrialised nations, according to the International Monetary Fund (IMF). Inflation will be the highest among the club both this year ...